Antimicrobial potential of lycosin-I, a cationic and amphiphilic peptide from the venom of the spider Lycosa singorensis

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 900-910

  Tan, H ^a   Ding, X ^a   Meng, S ^a,b   Liu, C ^a   Wang, H ^a   Xia, L ^a   Liu, Z ^a   Liang, S ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

^b Taizhou Yellnew Biotech Co Ltd   (China)

Author keywords

Antimicrobial activity; Antimicrobial peptide; Cell membrane permeabilization; Lycosin I; Spider venom

Indexed keywords

AMPICILLIN; ANTIMICROBIAL CATIONIC PEPTIDE; ERYTHROMYCIN; KANAMYCIN; LYCOSIN I; MAGAININ 2; MAGNESIUM; SPIDER VENOM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL PERMEABILIZATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HEMOLYSIS; HUMAN; HUMAN CELL; KINETICS; LYCOSA SINGORENSIS; MEMBRANE PERMEABILIZATION ASSAY; MICRODILUTION ASSAY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SPIDER;

EID: 84881343780     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113139990045     Document Type: Article

References (58)

1. Alabi AA, Bahamonde MI, Jung HJ, Kim JI, Swartz KJ. Portability of paddle motif function and pharmacology in voltage sensors. Nature 2007; 450: 370-5.
2. Bohlen CJ, Priel A, Zhou S, King D, Siemens J, Julius D. A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. Cell 2010; 141: 834-45.
3. Corzo G, Escoubas P. Pharmacologically active spider peptide toxins. Cell Mol Life Sci 2003; 60: 2409-26.
4. Escoubas P. Molecular diversification in spider venoms: a web of combinatorial peptide libraries. Mol Divers 2006; 10: 545-54.
5. Estrada G, Villegas E, Corzo G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat Prod Rep 2007; 24: 145-61
6. Lee SY, MacKinnon R. A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature 2004; 430: 232-5.
7. Mazzuca M, Heurteaux C, Alloui A, et al. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci 2007 10: 943-5.
8. Milescu M, Vobecky J, Roh SH, et al. Tarantula toxins interact with voltage sensors within lipid membranes. J Gen Physiol 2007; 130: 497-511.
9. Suchyna TM, Tape SE, Koeppe RE, Andersen OS, Sachs F, Gottlieb PA. Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. Nature 2004; 430: 235-40.
10. Yan L, Adams ME. Lycotoxins, Antimicrobial Peptides from Venom of the Wolf Spider Lycosa carolinensis. J Biol Chem 1998; 273: 2059-66.
11. Kuhn-Nentwig L, Müller J, Schaller J, Walz A, Dathe M, Nentwig W. Cupiennin 1, a new family of highly basic antimicrobial peptides in the venom of the spider Cupiennius salei (Ctenidae). J Biol Chem 2002; 277: 11208-16.
12. Kozlov SA, Vassilevski AA, Feofanov AV, Surovoy AY, Karpunin DV, Grishin EV. Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity. J Biol Chem 2006; 281: 20983-92.
13. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
14. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18: 24-30.
15. Fan Z, Cao L, He Y, et al. Ctriporin, a new anti-methicillin-resistant taphylococcus aureus peptide from the venom of the scorpion Chaerilus tricostatus. Antimicrob Agents Chemother 2011; 55: 5220-9.
16. Zhao Z, Ma Y, Dai C, et al. Imcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates. Antimicrob Agents Chemother 2009; 53: 3472-7.
17. Skarnes RC, Watson DW. Antimicrobial factors of normal tissues and fluids. Bacteriol Rev 1957; 21: 273-94.
18. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462: 11-28.
19. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009; 37: D933-7.
20. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22.
21. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
22. Huang Y, Huang J, Chen Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 2010; 1: 143-52.
23. Vizioli J, Salzet M. Antimicrobial peptides from animals: focus on invertebrates. Trends Pharmacol Sci 2002; 23: 494-6.
24. Gennaro R, Zanetti M. Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000; 55: 31-49.
25. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995; 13: 61-92.
26. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449-53.
27. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 1993; 53: 3052-7.
28. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996; 35: 11361-8.
29. Liu Z, Deng M, Xiang J, et al. A Novel Spider Peptide Toxin Suppresses Tumor Growth through Dual Signaling Pathways. Curr ol Med 2012; 12: 1350-60.
30. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
31. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1: 156-64.
32. Liu Z, Dai J, Dai L, et al. Function and solution structure of huwentoxin-X, a specific blocker of N-type calcium channels, from the Chinese bird spider Ornithoctonus huwena. J Biol Chem 2006; 281: 8628-35.
33. Li SA, Lee WH, Zhang Y. Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models. Antimicrob Agents Chemother 2012; 56: 3309-17.
34. Marra A, Girard D. Primary rodent infection models for testing antibacterial compound efficacy in vivo. Curr Protoc Pharmacol 2006; Chapter 13: Unit13A.4.
35. Dartois V, Sanchez-Quesada J, Cabezas E, et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 2005; 49: 3302-10.
36. Roth BL, Poot M, Yue ST, Millard PJ. Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain. Appl Environ Microbiol 1997; 63: 2421-31.
37. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1999; 1462: 1-10.
38. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 1998; 244: 253-7.
39. Dai T, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med 2010; 42: 38-44.
40. Corzo G, Villegas E, Gómez-Lagunas F, Possani LD, Belokoneva OS, Nakajima T. Oxyopinins, large amphipathic peptides isolated from the venom of the wolf spider Oxyopes kitabensis with cytolytic properties and positive insecticidal cooperativity with spider neurotoxins. J Biol Chem 2002; 277: 23627-37.
41. Sato H, Feix JB. Peptide-membrane interactions and mechanisms of membrane destruction by amphipathic a- helical antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1245-56.
42. Hancock RE, Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2: 79-83.
43. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-20.
44. Bradshaw JP. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 2003; 17: 233-40.
45. Afacan NJ, Yeung AT, Pena OM, Hancock RE. Therapeutic potential of hostdefense peptides in antibiotic-resistant infections. Curr Pharm Des 2012; 18: 807-19.
46. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16: 82-8.
47. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002; 66: 236-48.
48. Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1999; 1462: 71-87.
49. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by a-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999; 1462: 55-70.
50. Matsuzaki K, Murase O, Miyajima K. Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Biochemistry 1995; 34: 12553-9.
51. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
52. Ehrenstein G, Lecar H. Electrically gated ionic channels in lipid bilayers. Q Rev Biophys 1977; 10: 1-34.
53. Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogs with phospholipid membranes. Biochemistry 1992; 31: 12416-23.
54. Matsuzaki K, Murase O, Fujii N, Miyajima K. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore. Biochemistry 1995; 34: 6521-6.
55. Gazit E, Boman A, Boman HG, Shai Y. Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Biochemistry 1995; 34: 11479-88.
56. Naito A, Nagao T, Norisada K, Mizuno T, Tuzi S, Saitô H. Conformation and dynamics of melittin bound to magnetically oriented lipid bilayers by solid-state (31)P and (13)C NMR spectroscopy. Biophys J 2000; 78: 2405-17.
57. Hallock KJ, Lee DK, Ramamoorthy A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys J 2003; 84: 3052-60.
58. Henzler Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003; 42: 6545-58.